Effect of germanium-132 on galactose cataracts and glycation in rats.
Germanium compounds have been shown to be effective in preventing the formation of advanced glycation end-products and for reversible solubilization of glycated proteins. As protein glycation has been proposed to play a role in lens opacification, we initiated studies to evaluate the effects of 2-carboxyethyl germanium sesquioxide (germanium compound 132 or Ge-132) on galactose-induced cataractogenesis. For this study young Sprague-Dawley rats were fed a 50% galactose diet. One group of rats received topical saline and another group was administered Ge-132 in saline four times a day. The lenses were periodically examined with an ophthalmoscope and at desired intervals processed for light and scanning electron microscopy. Our observations, beginning at 3 days and continuing to 21 days of galactose feeding, exhibited the characteristic galactose-induced morphological alterations, which include the formation of vacuoles, cysts, membrane disruption and swelling of fibers and epithelial cells as well as disorganization of the bow in lenses of rats in both groups. However, in the majority of rats administered Ge-132 these alterations were delayed as compared to the lenses of rats administered saline. Our findings show that, although the initiation, progression and pattern of lens opacification in rats receiving saline and Ge-132 were similar, in the majority of lenses the progression and establishment of mature cataracts in the Ge-132 group of rats were delayed. Analysis of the water-soluble and water-insoluble lens-protein fractions for glycated proteins showed increased levels of the Amadori products and advanced glycation related fluorescent products in galactosemic rats treated with saline eye drops. In rats receiving the topical Ge-132 treatment the levels of these glycation products were substantially reduced to levels lower than control values. Prevention of glycation seems to be a mechanism by which cataract progression is delayed.
Unakar
N J
NJ
Department of Biological Sciences, Oakland University, Rochester, MI 48309-4401, USA.
Johnson
M
M
Tsui
J
J
Cherian
M
M
Abraham
E C
EC
D000818:Animals; D002386:Cataract / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D005690:Galactose; D005857:Germanium / Q000627:therapeutic use*; D006031:Glycosylation / Q000187:drug effects; D007908:Lens, Crystalline / Q000378:metabolism / Q000648:ultrastructure*; D008855:Microscopy, Electron, Scanning; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011422:Propionates; D051381:Rats; D017207:Rats, Sprague-Dawley
D009942:Organometallic Compounds; D011422:Propionates; D005857:Germanium; C066750:propagermanium; D005690:Galactose